2023
Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer
Kahn A, Golestani R, Harigopal M, Pusztai L. Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer. Breast Cancer Research And Treatment 2023, 201: 289-298. PMID: 37378695, DOI: 10.1007/s10549-023-06977-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPD-L1 expressionBreast cancerPD-L1Metastatic triple-negative breast cancerPD-L1 positive casesEarly-stage breast cancerPD-L1 protein expressionImmune checkpoint inhibitorsPD-L1 positivityPD-L1 statusProtein expressionWhole study populationPrimary breast tumorsNegative breast cancerConcordant negative resultsCheckpoint inhibitorsMultiple biopsiesPositive cancersCohen's kappa coefficientStudy populationE1L3N antibodyDiscordance rateBreast tumorsPositive casesSurgery in the Setting of Metastatic Breast Cancer
Plichta J, Taskindoust M, Greenup R. Surgery in the Setting of Metastatic Breast Cancer. Current Breast Cancer Reports 2023, 15: 37-47. DOI: 10.1007/s12609-023-00476-4.Peer-Reviewed Original ResearchMetastatic breast cancerSurvival benefitBreast cancerSurgical resectionPrimary tumorSelect patient groupsPotential survival benefitPrimary breast tumorsLocoregional treatmentMetastatic diseaseMost patientsPatient groupProspective studyRetrospective studySelect subgroupClinical scenariosBreast tumorsResectionTumorsCancerLimited benefitSurgeryPatientsMixed resultsDisease
2022
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.Peer-Reviewed Original ResearchConceptsBreast cancer metastasisReticuloendotheliosis viral oncogene homolog ACancer metastasisImmune suppressionM2 macrophagesWorse metastasis-free survivalMetastatic breast cancerMetastasis-free survivalV-rel avian reticuloendotheliosis viral oncogene homolog ACancer-related deathPrimary breast tumorsMultiple mouse modelsNF-κB signalingImmunocompetent settingNuclear factor-κB family membersMetastasis-promoting genesDistant metastasisMetastatic sitesPrimary tumorEffective therapyBreast cancerMetastasis treatmentMouse modelBreast tumorsMetastasis
2017
Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert B, Vieites B, Limon D, Kurman N, Ko K, Yu J, Chiang V, Poortmans P, Zagar T. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research And Treatment 2017, 167: 479-483. PMID: 28975433, DOI: 10.1007/s10549-017-4526-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSubsequent brain metastasesHuman epidermal growth factor receptor 2Brain metastasesCancer patientsEthical research committeeReceptor statusPrimary tumorProgesterone receptorEstrogen receptorEpidermal growth factor receptor 2Triple-negative profileGrowth factor receptor 2Primary breast cancerPrimary breast tumorsInternational multicenter studyFactor receptor 2Multicenter studyAvailable histologyResultsA totalBreast cancerReceptor 2ConclusionsThe majorityPatientsBreast tumors
2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Pavlovic M, Arnal-Estapé A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albéniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis R. Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. Journal Of The National Cancer Institute 2015, 107: djv256. PMID: 26376684, PMCID: PMC4681582, DOI: 10.1093/jnci/djv256.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorBone NeoplasmsBreast NeoplasmsCell Line, TumorDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticHeterograftsHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMiceMice, Inbred BALB COdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsProto-Oncogene Proteins c-mafUp-RegulationConceptsBreast cancer bone metastasisCopy number aberrationsCancer bone metastasisBone metastasesRisk of bone metastasisAssociated with bone metastasisBreast cancer cells in vivoPrimary breast tumorsBreast cancer patient populationCancer cells in vivoMetastasis to boneClinical follow-upBreast cancer cellsAssociated with riskCells in vivoCancer patient populationBone relapseCause-specific hazard modelBreast tumorsFollow-upMAF overexpressionMetastasisPatient populationProtein overexpressionCancer cells
2013
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Young Park S, Eileen Dolan M, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications 2013, 4: 1393. PMID: 23340433, PMCID: PMC3723106, DOI: 10.1038/ncomms2393.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell SurvivalCluster AnalysisCytoskeletonDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGATA3 Transcription FactorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInterleukin-11MiceMicrofilament ProteinsMicroRNAsPrognosisProtein-Tyrosine KinasesReal-Time Polymerase Chain ReactionSuppression, GeneticXenograft Model Antitumor AssaysConceptsMicroRNA-30cChemotherapy resistanceBreast tumorsMesenchymal transitionRelapse-free survivalBreast cancer patientsPrimary breast tumorsTumor prognostic markersTumor chemotherapy resistanceNovel therapeutic strategiesInterleukin 11 expressionCancer patientsPrognostic markerBreast cancerTherapeutic strategiesTherapy resistanceTumor progressionIL-11Interleukin-11Direct targetingTwinfilin-1TumorsChemoresistanceFamily membersMolecular mechanisms
2012
Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC).
Lustberg M, Miller B, Wu Y, Xue W, Deighan C, Carothers S, Berger M, Shapiro C, Chalmers J. Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 172-172. DOI: 10.1200/jco.2012.30.27_suppl.172.Peer-Reviewed Original ResearchBlood samplesBreast cancerLeukocyte populationsPeripheral blood leukocyte populationsNegative depletionAdvanced breast cancerMultiparameter flow cytometry analysisVenous blood samplesBlood leukocyte populationsPrimary breast tumorsMacrophages/monocytesProgression of diseaseBreast tumor stromaCell surface markersAdditional phenotypic characterizationFlow cytometry analysisPositive leukocytesBC patientsPeripheral bloodPredictive markerPoor responseCD 68Such tumorsPatient's stageT cellsLin28 regulates HER2 and promotes malignancy through multiple mechanisms
Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 2012, 11: 2486-2494. PMID: 22713243, DOI: 10.4161/cc.20893.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2HER2 expressionLin28 expressionEpidermal growth factor receptor 2Growth factor receptor 2Primary breast tumorsFactor receptor 2Cancer cell growthMajor therapeutic targetMultiple mechanismsAdvanced human malignanciesClinical outcomesPoor prognosisBreast cancerReceptor 2Therapeutic targetBreast tumorsNovel mechanistic insightsHuman malignanciesLin28 overexpressionReceptor tyrosine kinasesCancerCell proliferationHuman cancersPowerful predictorPTHrP and breast cancer: more than hypercalcemia and bone metastases
Boras-Granic K, Wysolmerski JJ. PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Research 2012, 14: 307. PMID: 22546075, PMCID: PMC3446368, DOI: 10.1186/bcr3129.BooksConceptsBone metastasesBreast cancerMMTV-PyMT miceNormal breast developmentPrimary breast tumorsHormone-related proteinBreast cancer susceptibility genesNew breast cancer susceptibility genesCancer patientsPrimary tumorCancer susceptibility genesClinical investigationBreast developmentBreast tumorsTumor growthPTHrPMetastasisHypercalcemiaTumorsCancerSusceptibility genesFurther researchPatientsMice
2011
Differential expression of arrestins is a predictor of breast cancer progression and survival
Michal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Research And Treatment 2011, 130: 791-807. PMID: 21318602, PMCID: PMC3156829, DOI: 10.1007/s10549-011-1374-9.Peer-Reviewed Original ResearchConceptsBreast cancer progressionBreast cancerCancer progressionArrestin2 expressionLuminal linesMyoepithelial cellsNormal human breast tissueMetastatic breast cancerLymph node metastasisPoor clinical outcomeIndependent prognostic markerPrimary breast tumorsBreast cancer cell linesG protein-coupled receptorsArrestin2 levelsPositive lymphCancer cell linesHazard ratioHuman breast tissueProtein-coupled receptorsNode metastasisClinical outcomesDuctal carcinomaTumor sizeNuclear grade
2010
The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE. The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Molecular Cancer 2010, 9: 150. PMID: 20550710, PMCID: PMC2894764, DOI: 10.1186/1476-4598-9-150.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorErbB ReceptorsEstrogen Receptor alphaFemaleGene ExpressionGene Expression RegulationHumansMammary Glands, AnimalMammary Glands, HumanMiceMice, TransgenicPregnancyReceptor, ErbB-4Receptors, ProgesteroneReverse Transcriptase Polymerase Chain ReactionSignal TransductionConceptsPgR expressionExpression of PgRBreast cancerERα coactivatorMammary glandHER4 intracellular domainProgesterone receptor expressionPositive breast carcinomaMalignant breast epitheliumPrimary breast tumorsMCF-7 variantEstrogen receptor coactivatorBreast tumor cell linesCell linesBreast tumor cellsTamoxifen responseMouse mammary glandProgesterone receptorReceptor expressionBreast carcinomaMCF-7 breast tumor cell linePatient responseBreast carcinogenesisEstrogen stimulationBreast epithelium
2009
CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence
Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, Hortobagyi GN, Hung M, Pusztai L, Delaloge S, Michiels S, Cristofanilli M. CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. The Oncologist 2009, 14: 1182-1188. PMID: 19939894, DOI: 10.1634/theoncologist.2009-0161.Peer-Reviewed Original ResearchConceptsPrimary breast tumorsCXCR4 expressionBone metastasesBreast tumorsClinical characteristicsDistant metastasisPrognostic valueHigh riskLigand stromal cell-derived factor-1Stromal cell-derived factor-1Cell-derived factor-1Bone-targeted agentsEarly breast cancerProspective clinical trialsCox regression modelNovel adjuvant strategyExpression of CXCR4Chemokine receptor 4Early metastatic processOccurrence of metastasesSpecific organ sitesCXCR4 tumorsDistant recurrenceOverall survivalAdjuvant strategies
2008
Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer. Clinical Cancer Research 2008, 14: 4455-4462. PMID: 18628459, PMCID: PMC5849429, DOI: 10.1158/1078-0432.ccr-07-5268.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAurora Kinase BAurora KinasesBiomarkers, TumorBlotting, WesternBreast NeoplasmsCell Line, TumorFemaleHistory, 17th CenturyHumansImage Processing, Computer-AssistedImmunohistochemistryKaplan-Meier EstimatePrognosisProtein Serine-Threonine KinasesTissue Array AnalysisConceptsBreast cancerB expressionAurora B expressionBreast tumorsHigh AuroraEarly-stage breast cancerHER-2/neuProgesterone receptor expressionSubset of patientsPopulation of patientsIndependent prognostic markerHigh nuclear gradePrimary breast tumorsCy5-conjugated antibodiesPathologic variablesPrognostic roleMultivariable analysisProspective studyNuclear gradePrognostic markerReceptor expressionClinical developmentPatientsPredictive roleCancer
2007
The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer
Jain A, Haisfield-Wolfe ME, Lange J, Ahuja N, Khouri N, Tsangaris T, Zhang Z, Balch C, Jacobs LK. The Role of Ultrasound-Guided Fine-Needle Aspiration of Axillary Nodes in the Staging of Breast Cancer. Annals Of Surgical Oncology 2007, 15: 462-471. PMID: 17985188, DOI: 10.1245/s10434-007-9623-1.Peer-Reviewed Original ResearchConceptsUltrasound-guided fine-needle aspirationSentinel node dissectionAxillary node dissectionPreoperative ultrasound-guided fine-needle aspirationPositive predictive valuePrimary tumor featuresFine-needle aspirationAxillary nodesNode dissectionTumor featuresAbnormal axillary nodesBreast cancer patientsLymph node pathologyPrimary breast tumorsRole of ultrasoundSuspicious nodesNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseDefinitive managementCancer patientsBreast cancerPredictive valueBreast tumorsUSFNA results
2000
Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy
Turner B, Gumbs A, Carbone C, Carter D, Glazer P, Haffty B. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 2000, 88: 1091-1098. PMID: 10699900, DOI: 10.1002/(sici)1097-0142(20000301)88:5<1091::aid-cncr21>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceMutant p53 protein overexpressionBreast carcinoma patientsP53 protein overexpressionBreast tumor recurrenceDistant disease-free survivalDisease-free survivalCase-control studyPrimary breast tumorsCarcinoma patientsMutant p53 proteinBreast tumor relapseRadiation therapyTumor recurrenceBreast tumorsFree survivalProtein overexpressionPrognostic significanceP53 proteinEstrogen receptorTumor relapseIndex caseP53 mutationsControl casesP53 protein immunoreactivity
1994
Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary
Yu H, Diamandis E, Levesque M, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. Journal Of Clinical Laboratory Analysis 1994, 8: 251-253. PMID: 7523638, DOI: 10.1002/jcla.1860080412.Peer-Reviewed Original ResearchConceptsProstate-specific antigenMetastatic ovarian cancerPrimary breast tumorsBreast tumorsOvarian cancerSpecific antigenPrimary ovarian cancer tumorsFavorable prognostic indicatorOvarian cancer tumorsMetastatic sitesTumor metastaticPrognostic indicatorBreast cancerPSA productionEctopic productionTumorsSteroid hormonesCancer tumorsCancerPatientsAntigenTreatmentLow levelsHigh levelsMetastatic
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply